TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

TrustFinance Global Insights
Mar 27, 2026
2 min read
14

Spain's IBEX 35 index concluded the trading week with a notable decline, closing 0.74% lower on Friday. The negative performance was a direct result of broad-based losses across several influential sectors, signaling bearish sentiment among investors in the Spanish market.
The downturn was primarily driven by weaknesses in the Consumer Goods, Building & Construction, and Financial Services & Real Estate sectors. Market breadth on the Madrid Stock Exchange confirmed the negative trend, with falling stocks outnumbering advancing ones by a significant margin of 124 to 67, while 16 stocks ended the session unchanged.
Among the session's worst performers were SOLARIA ENERGIA Y MEDIO AMBIENTE (BME:SLRS), which fell 4.37%, and Indra A (BME:IDR), declining 4.29%. In stark contrast, Enagas (BME:ENAG) emerged as the day's top performer, with its shares surging 16.96% to trade at a new 52-week high of 17.14 at the close.
The broad-based sector decline indicates widespread selling pressure. Market participants will be closely monitoring whether this downward momentum carries into the next trading sessions, with a focus on sector-specific catalysts and macroeconomic data for future direction.
Q: How much did the IBEX 35 index fall?
A: The IBEX 35 index declined by 0.74% at the close on Friday.
Q: Which sectors led the decline?
A: The main sectors contributing to the losses were Consumer Goods, Building & Construction, and Financial Services & Real Estate.
Q: What was the best-performing stock on the IBEX 35?
A: Enagas (BME:ENAG) was the top gainer, with its stock price increasing by 16.96%.
Source: Investing.com

TrustFinance Global Insights
AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.
Related Articles

27 Mar 2026
Kailera Therapeutics Files for Nasdaq IPO